Tylenol During Pregnancy Does Not Cause Autism or ADHD, Massive Sibling Study Finds

---

For years, a nagging fear has followed pregnant women into the medicine cabinet: could taking Tylenol, one of the few pain relievers considered safe during pregnancy, be linked to autism or ADHD in their children? The worry spread fast, fueled by headlines, earlier research, and even a prominent statement from the U.S. president. But a sweeping new study of more than 700,000 mother-child pairs points to a different source for that fear: shared family factors, not the drug itself.

Researchers in Hong Kong took a harder look by using a method that adds to a small but growing body of sibling-matched research: comparing brothers and sisters. Their study, published in the journal JAMA Internal Medicine, looked at children from the same family, where one was exposed to acetaminophen (the active ingredient in Tylenol, also known as paracetamol) before birth and another was not. By doing so, the team greatly reduced the influence of the genetic and household factors that had clouded earlier studies. The result was consistent: no evidence that prenatal acetaminophen exposure raised the risk of either autism or ADHD.

This reassurance lands at a time when public concern has been unusually high. Regulators including the World Health Organization and the UK’s medicines watchdog have already reaffirmed acetaminophen’s safety profile for use during pregnancy, calling it a reasonable and appropriate choice when clinically indicated. Yet persistent worry, amplified in part by political commentary, has left many expectant mothers confused and anxious. This study offers some of the strongest reassurance yet.

A Smarter Study Design Puts the Acetaminophen-Autism Link to the Test

Past studies that flagged a possible link between prenatal acetaminophen use and autism or ADHD shared one fundamental problem. Families that use more medication during pregnancy may differ from those that don’t in all sorts of invisible ways: their genetic makeup, their overall health, their access to medical care. Those hidden differences, not the drug, may have been driving the apparent risk. It is a classic problem in medical research, and it is notoriously hard to fix.

To address it, the Hong Kong team built what researchers call a sibling-matched study. Instead of comparing unrelated children from across the population, the researchers zeroed in on families where one child had been exposed to acetaminophen before birth and a sibling had not. Because these siblings share the same mother, the same home, the same genes, and the same family environment, any difference in health outcomes between them is far less likely to trace back to those hidden background factors.

Starting with 708,020 mother-child pairs drawn from Hong Kong’s public health records spanning 2001 to 2023, the team built a focused group of 124,333 children for the autism analysis and 97,285 for the ADHD analysis. Roughly 43% of pregnancies in the original pool involved some acetaminophen use, based on prescription records.

What the Numbers Actually Showed

Among matched siblings, children whose mothers took acetaminophen during pregnancy were no more likely to be diagnosed with autism than those whose mothers did not. The same held for ADHD. That result stayed put no matter how the researchers sliced the data, whether they looked at which trimester the medication was used, how often it was taken, or how high the dose was. No pattern emerged suggesting more exposure meant more risk.

Follow-up ran a median of more than 10 years for the autism group and over 11 years for the ADHD group, a long window to watch for diagnoses. During that time, 3,445 children in the autism group were diagnosed with autism, and 5,168 in the ADHD group received an ADHD diagnosis. Yet when exposed siblings were compared with unexposed ones inside the same families, the risk was essentially identical between the two.

Perhaps the most telling piece of evidence came from what researchers call a “negative control” test. They checked whether mothers who took acetaminophen in the year before getting pregnant, a stretch when the drug cannot possibly affect a fetus, had children with higher rates of autism or ADHD. Under a standard analysis, they did. That makes no biological sense, and it points toward a likelier explanation: families with a genetic tendency toward these conditions are simply more likely to use pain medication overall, at any point in time. On that reading, the apparent link reflects shared family factors more than the medication itself.

Why Earlier Studies Got It Wrong

When the researchers ran the same kind of conventional analysis that earlier studies had used, dropping the sibling-matching step, they reproduced those older, alarming results. A standard comparison showed what looked like a real increase in autism and ADHD risk among children whose mothers used acetaminophen during pregnancy, matching what past research had reported. Once the sibling comparison was applied, that apparent risk vanished.

This pattern has now surfaced in sibling-matched studies from Norway, Sweden, Japan, and now Hong Kong, four very different populations with different genetics, cultures, and health systems. In every one, accounting for shared family factors made the apparent link between prenatal acetaminophen and neurodevelopmental conditions disappear.

Acetaminophen Remains the Safer Choice During Pregnancy

Study authors placed their conclusion in a practical context. Acetaminophen is the first-line recommendation for pain and fever during pregnancy precisely because the alternatives carry documented risks of their own. Anti-inflammatory drugs such as ibuprofen have been linked to miscarriage and to kidney problems in children exposed before birth. Opioid painkillers can trigger withdrawal symptoms in newborns. Untreated fever during pregnancy has itself been identified in research as a possible risk factor for neurodevelopmental problems.

Avoiding paracetamol without good reason, the authors cautioned, could leave pain and fever untreated or push patients toward those more harmful alternatives, both of which pose risks to the pregnancy and the developing fetus. Their guidance lines up with major health regulators: acetaminophen, used at the lowest effective dose for as short a time as needed, remains a reasonable and appropriate option.

A few limits are worth noting. The analysis captured only prescription-based acetaminophen use inside Hong Kong’s public system, so over-the-counter purchases went untracked, and additional testing showed that gap could not account for the lack of any link. Across more than two decades of data, across multiple continents, and now across a large Chinese population studied this way for the first time, the conclusion holds. Worry that acetaminophen during pregnancy alters a child’s developing brain looks, on this evidence, more like a reflection of family biology than anything the drug was doing. For the many pregnant women who have reached for that bottle, the science now says there was little reason to fear.

Disclaimer: This article summarizes a single peer-reviewed observational study and is intended for general information, not medical advice. Observational research can identify patterns but cannot prove that a medication does or does not cause a condition. Individual circumstances vary, and pregnant women should not start, stop, or change any medication based on this article. Anyone with questions about pain relief or medication use during pregnancy should speak with a doctor, pharmacist, or other qualified healthcare provider.

---